Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Skin-Saving paste for cancer radiation falls short in tiny trial

NCT ID NCT01408407

Prevention Sponsor: Sir Mortimer B. Davis - Jewish General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether Alkagin paste could prevent skin damage in patients receiving radiation for anal, rectal, or gynecological cancers. Only 2 people enrolled before the trial was stopped early. Because of this, we cannot draw any reliable conclusions about the paste's effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Alkagin paste
What this could lead to
If it worked, this could offer a way to prevent painful skin burns in patients receiving radiation for pelvic cancers.
What could go wrong
The trial was terminated early with only 2 participants, so we have very little data. It is unclear if Alkagin paste is effective or safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

2 people

The number who actually took part.

Start date

Dec 2011

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients receiving a dose of 45 Gy or more with concomitant chemotherapy to the perineal skin (for treatment of anal canal, low rectal or gynecological cancer). * Patients able to understand and sign an informed consent form. * Patients that do not have active connective tissue disorders. * Patients 18 years or older. * Patients that did not receive any previous radiation. * Patients that do not have any known allergy to any ingredients of the Alkagin Paste * Patients need to be able to apply the creams themselves or have help with applying the creams. * Patients who have been offered to purchase silver clear underpants but have refused Exclusion Criteria: * Patients that have a type V or type VI skin type according to the Fitzpatrick scale (because these patients will likely have less radiodermatitis and if they do, it will be harder to evaluate it) The Fitzpatrick Scale: * Type I (scores 0-7) White; very fair; freckles. Always burns, never tans * Type II (scores 8-16) White; fair. Usually burns, tans with difficulty * Type III (scores 17-25) Beige; very common. Sometimes mild burn, gradually tans * Type IV (scores 25-30) Beige with a brown tint; typical Mediterranean Caucasian skin. Rarely burns, tans with ease * Type V (scores over 30) Dark brown. Very rarely burns, tans very easily * Type VI Black. Never burns, tans very easily 2\) Patients with an allergic reaction to Alkagin Paste

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anal canal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anal canal cancer anus neoplasm female reproductive organ cancer rectal cancer rectal neoplasm Urogenital Neoplasms radiodermatitis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anus neoplasms Rectal neoplasms Urogenital neoplasms

Contacts and locations

Locations

  • Jewish General Hospital

    Montreal, Quebec, H3T 1E2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.